When Ethna Renner was diagnosed with breast cancer in 2019, it was the most daunting news she had ever received. Suddenly she was faced with something she had no control over.
Metavivors and BCAC are delighted that two vital breast cancer medicines will soon be funded.
Breast Cancer Aotearoa Coalition (BCAC) stands with all people living with advanced breast cancer and their supporters who have advocated for changes in medicines funding and the health system.
Today (8 August 2019) PHARMAC released a proposal to fund Kadcyla (trastuzumab emtansine, T-DM1) for women with advanced HER2 positive breast cancer.
BCAC media release, 28 July 2019
Breast Cancer Aotearoa Coalition (BCAC) welcomes the announcement that if elected National would set up an independent cancer agency to ensure every New Zealander gets high-quality cancer care and to eliminate post code inequities.
UK medicines assessor NICE (National Institute for Health and Care Excellence) has just recommended another combination of drugs for women with advanced hormone-receptor-positive breast cancer. Ribociclib is one of three drugs in the CDK 4/6 inhibitor class, which can extend and improve the lives of women with this type of breast cancer.
Progress continues to be made through world-leading research to identify which treatments will work best for different sub-types of breast cancer.
Breast Cancer Aotearoa Coalition (BCAC) is 100% behind Blair Vining’s petition to Parliament calling for a national cancer agency to address New Zealand’s cancer death rates.
Malaghan Institute media release